Table 3.
Phase III study results for platinum sensitive recurrent ovarian cancer.
| PTX/CBOCA (COOP) | PTX/CBOCA | GEM/CBOCA | PLO/CBOCA | PLO/CBOCA | ||
|---|---|---|---|---|---|---|
| versus Pt combination | versus CBDCA | versus CBDCA | versus CBDCA | versus PTX/CBOCA | ||
| Dose (mg/m2) | 175–185/ AUC 5 (50–75) | 175/AUC 5 | 1000/AUC 4 | 30/AUC 5 | 30/AUC 5 | |
| versus AUC 5 (50–75) | versus AUC 5 | versus AUC 5 | versus AUC 5 | versus 175/AUC 5 | ||
| Author | González-Martín et al. | Pfisterer et al. | Alberts et al. | Pujiade-Lauraine et al. | ||
| ICON4/ [6] | GEICO [7] | AGO OVAR, [8] | SWOG [9] | GClG [10] | ||
| Study group | AGO-OVAR2.2 | NCIC CTG, EORTC GCG | ||||
| Number of patients | 392 versus 410 | 41 versus 40 | 178 versus 178 | 31 versus 30 | 466 versus 508 | |
| Response rate (%) | 66 versus 54 | 75.6 versus 50.0* | 47.2 versus 30.9* | 52 versus 29 | NA | |
| PFS (months) | 12 versus 9* | 12.2 versus 8.4* | 8.6 versus 5.8* | 12 versus 8* | 11.3 versus 9.4* | |
| OS (months) | 29 versus 24* | NA | 18 versus 17.3 | 26 versus 18* | NA | |
PTX: paclitaxel; PT: cisplatin or carboplatin.
CBDCA: carboplatin; GEM: gemcitabine; PLD: pegylated Iiposomal doxorubicin.
PFS: progression free interval; PS: overall survival.
NA: not applicable.
*Statistically significant.